Drug Trial Radar · NCT06546735
Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
816
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Apr 30, 2028
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical trial to evaluate the fixed-dose combination (N0728), with the aim of providing the Brazilian market with an alternative, potentially effective, safe and convenient therapeutic approach for the treatment of Lower Urinary Tract Symptoms (LUTS) in men with Benign Prostatic Hyperplasia (BPH). The fixed-dose combination has synergistic action between drugs from different classes and offers significant potential advantages, such as better adherence to treatment. The trial will assess the non-inferiority in efficacy and safety of the proposed fixed-dose combination compared to alpha-adrenergic antagonists.
Conditions
- Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Interventions
N0728Drug
1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
Vesomni®Drug
1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean number of urgency episodes per dayTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eurofarma Laboratorios S.A
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.